<DOC>
	<DOCNO>NCT01185964</DOCNO>
	<brief_summary>The main purpose study gather information use investigational drug call IMC-3G3 drug soft tissue sarcoma call doxorubicin .</brief_summary>
	<brief_title>A Study IMC-3G3 Soft Tissue Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Dexrazoxane</mesh_term>
	<mesh_term>Razoxane</mesh_term>
	<criteria>The patient histologically cytologicallyconfirmed malignant soft tissue sarcoma ( STS ) , include uterine leiomyosarcoma The patient advance STS , amenable treatment surgery radiotherapy The patient 's Eastern Cooperative Oncology Group ( ECOG ) performance status 02 The patient available tumor tissue either primary metastatic tumor determination PDGFRα expression The patient adequate hematologic function define absolute neutrophil count ( ANC ) ≥ 1500 μL , hemoglobin ≥ 9.0 g/dL , platelet count 100,000/μL obtain within 2 week prior study entry The patient adequate hepatic function define total bilirubin ≤ 1.5 mg/dL , aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 3.0 time upper limit normal ( ULN ) The patient adequate renal function define serum creatinine ≤ 1.5 × institutional ULN . If creatinine ULN , patient 's creatinine clearance ≥ 45 mL/min The patient urinary protein ≤ 1+ dipstick routine urinalysis ; urine dipstick routine analysis ≥ 2+ , 24hour urine protein must demonstrate &lt; 1 g protein 24 hour allow participation Because teratogenicity IMC3G3 know , woman childbearing potential ( WOCBP ) sexually active male must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation The patient histologically cytologicallyconfirmed Kaposi 's sarcoma The patient untreated central nervous system metastases The patient receive prior treatment doxorubicin , daunorubicin , idarubicin , and/or anthracyclines anthracenediones ( ie , mitoxantrone ) The patient receive prior radiation therapy mediastinal/pericardial area The patient history another primary cancer , exception ) curatively resect nonmelanomatous skin cancer ; b ) curatively treated cervical carcinoma situ ; c ) primary solid tumor treat curative intent , know active disease present , treatment administer last 3 year prior study entry The patient receive concurrent treatment anticancer therapy , include chemotherapy , immunotherapy , hormonal therapy , radiotherapy , chemoembolization , target therapy , investigational agent The patient elective plan major surgery perform course study The patient uncontrolled intercurrent illness include , limited , ongoing active infection , require parenteral antibiotic , symptomatic congestive heart failure , severe myocardial insufficiency , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement The patient unstable angina pectoris , angioplasty , cardiac stenting , myocardial infarction 6 month prior study entry The patient know immunodeficiency virus ( HIV ) infection The patient , female , pregnant lactate The patient know allergy treatment component</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Sarcoma , Soft Tissue</keyword>
	<keyword>Advanced Soft Tissue Sarcoma</keyword>
</DOC>